A letter written from 81 scientists and sent to the Bundestag (federal parliamentarians) argues compulsory vaccination is “not necessary, not appropriate and therefore unconstitutional”.
The scientists and scholars not only cited inalienable fundamental rights of citizens, but stated that mandatory vaccination is “not appropriate because of a high potential for risk” and that “side effects reported relative to other vaccines are enormous.”
The letter included a 70-page thesis underpinning why a Corona vaccination requirement is unconstitutional. It concludes: “Mandatory vaccination is neither appropriate, necessary, nor adequate to effectively reduce serious illness and prevent significant health care overuse.”
At least 80 percent unreported
The Group of 81 also calculated “a rate of at least 80 percent of unreported suspected cases of vaccine side effects.”
They also warned of “alarming safety signals, namely evidence of an increase in deaths as well as certain disease patterns such as myocarditis and pericarditis that occurred parallel to the vaccination campaigns.
The scientists noted in their letter to the legislators that from a legal point of view, “the first principle is that the burden of proof lies with the legislator” and “that unresolved serious concerns on only one of the four points are sufficient to declare a vaccination requirement unconstitutional”:
1. The right to self-determination, which is protected by fundamental rights, prohibits obliging individuals to vaccinate for their own protection. Under constitutional law, only the goal of protecting others is permissible, although this must not involve the absolute exclusion of any risk to the health of third parties, which the state cannot otherwise guarantee. Only two goals appear permissible here: a.) to reduce the number of severe diseases (intensive care patients and deaths) to a level that corresponds to that of other infectious diseases; b.) to prevent a significant overload of the health care system.
2. The appropriateness of compulsory vaccination is doubtful, because the available COVID vaccines do not generate sufficient immunity and thus do not provide sufficient protection from others: a) After a few weeks, vaccination not only no longer has a positive effect on the probability of infection, but may even increase this probability – as currently shown by Omicron; b) Vaccination has only a small effect on the severity of the disease, which decreases in a short period of time; c) People with vaccination are no less infectious when infected than people without vaccination. So vaccination cannot break chains of infection.
3. The necessity of a general vaccination obligation is to be denied, because a) the special danger of COVID-19 is no longer given. With the emergence of the Omicron variant, it is considered that the number of diseases with severe course has reached the level of a normal seasonal influenza; b) vaccination is not without alternative, because there are highly effective therapies as well as preventive measures available; c) a significant overload of the health care system has not occurred.
4. Mandatory vaccination is not appropriate because the available vaccines are not only not safe, but have an unprecedented risk potential: (a) measured by the fact that COVID-19 vaccines are novel drugs conditionally approved under special conditions, and their medium or long-term risk potential has not been adequately studied; (b) measured by the dangerousness and frequency of vaccine side effects documented by the Paul Ehrlich Institute; c) measured by a justified estimate of unrecorded side effects of at least 80 percent; d) measured by an unexplained high number of deaths, especially in the middle age groups into adolescence, which is temporally related to the vaccinations; e) measured by the emerging broad spectrum of side effects, whose extent of danger can only be estimated in the long term.”
The scientists write that they have showed that “valid concerns exist with respect to all of the above criteria” and thus a mandatory vaccination “would be unconstitutional.”
1 Ioannidis JPA. Infection Fatality Rate of COVID-19 Inferred from Seroprevalence Data, Bull World Health Org 2021, 99, Nr. 1, https://doi.org/10.2471/BLT.20.265892
2 Ioannidis JPA. Reconciling Estimates of Global Spread and Infection Fatality Rates of COVID‐19: An Overview of Systematic Evaluations. Europ J Clin Invest 2021, 51, Nr. 5, https://doi.org/10.1111/eci.13554
3 Axfors C, Ioannidis JPA. Infection fatality rate of COVID-19 in community-dwelling populations with emphasis on the elderly: An overview. https://doi.org/10.1101/2021.07.08.21260210
4 Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 21. 20 August 2021, Tabelle 3 auf Seite 15. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1012644/Technical_Briefing_21.pdf
5 Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. https://doi.org/10.1101/2022.01.11.22269045
6 https://en.wikipedia.org/wiki/Influenza_pandemic#cite_note-nfp:0-37
7 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N Engl J Med 2020;383:2603–2615, DOI:10.1056/NEJMoa2034577
8 Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, u. a. BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med 2021;384:1412–1423.
9 Kampf G. The epidemiological relevance of the COVID-19-vaccinated population is increasing. Lancet Regional Health – Eur, 2021, 11, https://doi.org/10.1016/j.lanepe.2021.100272; die Originaldaten sind vom Robert-Koch-Institut, https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Wochenbericht/
Wochenbericht_2021-07-22.pdf?__blob=publicationFile
10 Mizrahi B, Lotan R, Kalkstein R, et al. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Comm 2021, https://doi.org/10.1038/s41467-021-26672-3
11 Levin EG, Lustig Y, Cohen C, Fluss R, et al. Waning Immune Humoral Response to BNT162b2 COVID-19 Vaccine over 6 Months. New Eng J Med 2021, 385:e84.
12 Keehner J, Horton LE, Binkin NJ, Laurent LC, Pride D, Longhurst CA, et al. Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce. N Engl J Med 2021;385:1330–1332
13 Thomas SJ, Moreira ED, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months. New England Journal of Medicine 2021, https://doi.org/10.1056/NEJMoa2110345
14 Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 2021, doi:10.1016/S0140-6736(21)02183-8
15 Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. New England Journal of Medicine 2021, doi:10.1056/NEJMoa2114114
16 Nordström P, Ballin M, Nordström A. Effectiveness of COVID-19 vaccination against risk of symptomatic infection, hospitalization, and death up to 9 months: a Swedish total-population cohort study. Lancet (preprint), https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3949410, aufgerufen am 10.02.2022
17 Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, et al. Protection of BNT162b2 Vaccine Booster against COVID-19 in Israel. N Engl J Med 2021;385:1393–1400.
18 Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, et al. Protection by 4th dose of BNT162b2 against Omicron in Israel. https://doi.org/10.1101/2022.02.01.22270232
19 Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022. MMWR, 2022, 77(7), 255-263. Viele Autoren dieser Studie haben Interessenverflechtungen mit großen Pharma-Unternehmen angegeben.
20 Regev-Yoshai G, Gohen T, Gilboa M, Mandelboim M, Indenbaum V, et al. 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC. https://doi.org/10.1101/2022.02.15.22270948
21 https://www.israelnationalnews.com/news/321674
22 Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Inf 2021, https://doi.org/10.1016/j.cmi.2021.06.036.
23 Hansen CH, Schelde AB, Moustsen-Helm IR, Emborg HD, et al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. https://doi.org/10.1101/2021.12.20.21267966
24 RKI Wochenberichte, 14. Dezember 2021 und 6. Januar 2022.
25 Lyngse FP, Mortensen LH, Denwood MJ, Christiansen LE, et al. SARS-CoV-2 Omicron VOC Transmission in Danish Households. https://doi.org/10.1101/2021.12.27.21268278
26 Collie S, Champion J, Moultrie H, Bekker L-G, Gray G, Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med 2022; 386:494-496
27 Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. Doi: 10.1101/2022.01.11.22269045
28 Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 21. 20 August 2021, Tabelle 3 auf Seite 15. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1012644/Technical_Briefing_21.pdf
29 Subramanian SV, Kumar A. Increases in COVID‑19 are unrelated to levels of vaccination across 68 countries and 2947 counties in the United States. Europ J Epidemiol 2021, https://doi.org/10.1007/s10654-021-00808-7
30 Beattie KA. Worldwide Bayesian Causal Impact Analysis of Vaccine Administration on Deaths and Cases Associated with COVID-19: A Big Data Analysis of 145 Countries. DOI:10.13140/RG.2.2.34214.65605
31 Neil M, et al. Latest Statistics on England Mortality Data Suggest Systematic Mis-Categorisation of Vaccine Status and Uncertain Effectiveness of COVID-19 Vaccination, https://doi.org/10.13140/RG.2.2.14176.20483
32 Sheehan MM, Reddy AJ, Rothberg MB. Reinfection Rates among Patients who Previously Tested Positive for COVID-19: a Retrospective Cohort Study. https://doi.org/10.1101/2021.02.14.21251715
33 Kim P, Gordon SM, Sheehan MM, Rothberg MB. Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Natural Immunity and Protection Against the Delta Variant: A Retrospective Cohort Study, Clin Infect Dis 2021;20:1–6.
34 Gazit S, Shlezinger R, Perez G, Lotan R, et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. https://doi.org/10.1101/2021.08.24.21262415
35 Altarawneh H, Chemaitelly H, Tang P, Hasan MR, et al. Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant. https://doi.org/10.1101/2022.01.05.22268782, Daten aus der Tab.3.
36 Abu-Raddad, LJ, Chemaitelly H, Bertollini R. Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections. New Eng J Med 2021, 385:2487–2489, https://doi.org/10.1056/NEJMc2108120
37 Acharya CB, Schrom J. Mitchell AM, et al. No significant difference in viral load between vaccinated and unvaccinated, asymptomatic and symptomatic groups infected with SARS-CoV-2 delta variant. https://doi.org/10.1101/2021.09.28.21264262
38 Hagan LM, McCormick DW, Lee C, et al. Outbreak of SARS-CoV-2 B.1.617.2 (delta) variant infections among incarcerated persons in a federal prison—Texas, July–August 2021. Morb Mortal Wkly Rep 2021, 70: 1349-1354
39 Bergwerk M, Gonen T, Lustig Y, et al. COVID-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021, 385: 1474-1484
40 Wilder-Smith A. What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant? Lancet Infect Dis 2021, https://doi.org/10.1016/S1473-3099(21)00690-3
41 Kuhlmann C, Mayer CK, Claassen M, et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet 2022, 399, P625-626
42 Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England – Technical Briefing 20 [Internet]. 2021 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf, aufgerufen am 13.02.2022
43 Riemersma KK, Grogan BE, Kita-Yarbro A, Halfmann PJ, et al. Shedding of Infectious SARS-CoV-2 Despite Vaccination. https://doi.org/10.1101/2021.07.31.21261387
44 Singanayagam A, Hakki S, Dunning J, Madon KJ, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis, 2021, https://doi.org/10.1016/S1473-3099(21)00648-4
45 Lyngse FP, Mortensen LH, Denwood MJ, Christiansen LE, et al. SARS-CoV-2 Omicron VOC Transmission in Danish Households. https://doi.org/10.1101/2021.12.27.21268278
46 Thacker PD. COVID-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial. Brit Med J 2021, 375: n2635
via NoTricksZone
March 11, 2022
You must be logged in to post a comment.